|File:Remoxipride Structural Formulae.png|
|Systematic (IUPAC) name|
|ATC code||N05AL04 (WHO)|
|Molar mass||371.27 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Remoxipride (Roxiam) is an atypical antipsychotic which was previously used in Europe for the treatment of schizophrenia but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D2 and D3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|35px||This drug article relating to the nervous system is a stub. You can help ssf by expanding it.|
- José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
- Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990). "Biochemical pharmacology of the atypical neuroleptic remoxipride". Acta Psychiatrica Scandinavica. Supplementum. 358: 27–36. PMID 1978484.